CHA Bundang Medical Center has become the first in Asia (the second in the world) to confirm that the transplantation of human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) cells is effective in treating age-related macular degeneration (AMD) and Stargardt disease (juvenile macular degeneration) without causing dangerous side effects. Hence CHA Bundang Medical Center is now on the fast track to developing the world’s first hESC-based therapeutic product.
A Korean research team, led by Professor Song Won-Kyung from CHA Bundang Medical Center, and CHA Biotech (a leading S. Korea-based biotechnology firm focused on stem cell therapies) jointly issued an interim report on their clinical trial of a human embryonic stem cell (hESCs)-based therapy for retinal diseases and the report was published in the journal Stem Cell Reports, the world’s leading platform for high quality peer-reviewed full-text papers, according to CHA Biotech (…)
The study published in Stem Cell Reports also features the research team’s 12-month post-transplantation follow-up assessment of the four patients (two with AMD and the other two with Stargardt disease). None of the four exhibited serious side effects seen with other stem cell therapies and three of them actually had their vision improved.